Medicus Pharma Ltd. (MDCX) Fair Value 2026

MDCX · Drug Manufacturers - General ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (40/100)

Quick Summary — As of 2026-08-28, Medicus Pharma Ltd. (MDCX) trades at $0.26. QOC: 4.0/10. Value Trap Risk: 40/100 (WARN). 1/13 models active.

Key Facts

Ticker
MDCX
Price
$0.26
Quality Score
4.0/10
Value Trap Risk
40/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +2.5% upside with 28% confidence
Risk: Value Trap score of 40 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give MDCX?

1 Intrinsic Value Models vs. Current Price ($0.26)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.26 +2.5%

All Models Active

All 1 models are displayed above.

What Is Medicus Pharma Ltd. (MDCX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Medicus Pharma Ltd.'s intrinsic value is estimated at a median $0.26, showing conflicting signals at the current price of $0.26. While the median implied return is +2.5%, model disagreement is elevated with a gap of +0.0% between the most bullish and bearish estimates.

What Do the Models Say About MDCX?

1 of 13 models are currently active for MDCX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does MDCX Rank in Drug Manufacturers - General?

Among 21 Drug Manufacturers - General stocks, MDCX ranks #19 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.

Medicus Pharma Ltd.'s positioning within the Drug Manufacturers - General segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is MDCX a Value Trap?

CirclFi's Value Trap algorithm assigns MDCX a score of 40/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Medicus Pharma Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Medicus Pharma Ltd. earns a quality score of 4.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MDCX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MDCX's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Medicus Pharma Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - General Stocks Should You Also Analyze?

10 related Drug Manufacturers - General stocks with 13-model coverage

MIRAMIRA Pharmaceuticals, Inc.QOC 4.7NVSNovartis AGQOC 2.8SCLXScilex Holding CompanyQOC 5.2NSRXNasus Pharma Ltd.QOC 2.7AMRNAmarin Corporation plcQOC 6.1GILDGilead Sciences, Inc.QOC 9.7LLYEli Lilly and CompanyQOC 9.4BMYBristol-Myers Squibb CompanyQOC 8.5PFEPfizer Inc.QOC 7.5MRKMerck & Co., Inc.QOC 9.6

Read investment analysis: MIRA · NVS · SCLX · NSRX · AMRN · GILD · LLY · BMY · PFE · MRK

Which Other Stocks Have a Similar Quality Score to MDCX?

7 companies across all industries closest to MDCX’s Quality of Company score of 4.0/10.

BLNEBeeline Holdings, Inc.QOC 4.0BCABBioAtla, Inc.QOC 4.0MBIOMustang Bio, Inc.QOC 4.0CVMCEL-SCI CorporationQOC 3.9BDPTBioAdaptives, Inc.QOC 4.0QSEPQS Energy, Inc.QOC 3.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BLNE · BCAB · MBIO · CVM · BDPT · QSEP · NVDA

What Else Do Investors Ask About Medicus Pharma Ltd.’s Valuation?

What is Medicus Pharma Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Medicus Pharma Ltd. (MDCX). The Quality of Company score is 4.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MDCX overvalued or undervalued right now?

At $0.26, 1 of 1 active models suggest MDCX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Medicus Pharma Ltd.'s business model in Drug Manufacturers - General.

What does a Quality of Company score of 4.0 mean for MDCX?

Medicus Pharma Ltd.'s QOC of 4.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MDCX?

CirclFi analyzes MDCX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MDCX a value trap in 2026?

Medicus Pharma Ltd.'s Value Trap score is 40/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Medicus Pharma Ltd. (MDCX) a Quality of Company score of 4.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/MDCX/ · Methodology
Primary sources for this MDCX valuation
  • Financial statements: Medicus Pharma Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001997296) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MDCX as of ; valuations recomputed .